Global Cholesterol Lowering Biologic Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cholesterol Lowering Biologic Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
The cholesterol lowering biologic drugs offers a new, revolutionary alternative for people fighting with cholesterol with the same old treatments. The old method of treating cholesterol elevated levels includes a change in diet and consuming statin pills to prevent the body from making more bad cholesterol. The new class of PCSK-9 inhibitors is being approved by the FDA which works by helping the liver flush out the bad cholesterol instead of preventing the body from making low-density lipoproteins. The FDA has till now approved only two drugs Praluent and Repatha, both made from living things. The PCSK-9 is a protein which binds to the receptors, those which are responsible for getting the bad cholesterol out of the body.
Cholesterol Lowering Biologic Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cholesterol Lowering Biologic Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
The cholesterol lowering biologics drug market is expected to boom owing to the number of population with high cholesterol levels, sedentary lifestyle and increasing research developments. According to the Indian Council of Medical Research, at least three-fourth of the country’s population has dyslipidemia, a condition where the individual has abnormal levels of triglycerides or cholesterol. The risk factors are obesity, hypertension poor lifestyle habits and diabetes. Moreover, the demand for biologics is driven by the dramatic shift in production technology and an expansion of targeted diseases.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cholesterol Lowering Biologic Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals
Segment by Type
Oral
Injectable
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Cholesterol Lowering Biologic Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cholesterol Lowering Biologic Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cholesterol Lowering Biologic Drugs industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Cholesterol Lowering Biologic Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cholesterol Lowering Biologic Drugs introduction, etc. Cholesterol Lowering Biologic Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Cholesterol Lowering Biologic Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Cholesterol Lowering Biologic Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cholesterol Lowering Biologic Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
The cholesterol lowering biologics drug market is expected to boom owing to the number of population with high cholesterol levels, sedentary lifestyle and increasing research developments. According to the Indian Council of Medical Research, at least three-fourth of the country’s population has dyslipidemia, a condition where the individual has abnormal levels of triglycerides or cholesterol. The risk factors are obesity, hypertension poor lifestyle habits and diabetes. Moreover, the demand for biologics is driven by the dramatic shift in production technology and an expansion of targeted diseases.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cholesterol Lowering Biologic Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals
Segment by Type
Oral
Injectable
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Cholesterol Lowering Biologic Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cholesterol Lowering Biologic Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cholesterol Lowering Biologic Drugs industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Cholesterol Lowering Biologic Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cholesterol Lowering Biologic Drugs introduction, etc. Cholesterol Lowering Biologic Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Cholesterol Lowering Biologic Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices